InjectSense

InjectSense is pioneering a new category of digital health through its ultra-miniaturized, implantable sensor platform designed for continuous, long-term physiological monitoring. The company's core innovation lies in merging semiconductor manufacturing techniques—specifically wafer-scale packaging for scalability—with medical device development to create autonomous, rechargeable, and wireless sensors. Having completed its first human implantation in 2024, InjectSense is initially targeting the glaucoma market with a sensor smaller than a grain of rice, aiming to shift disease management from episodic clinic measurements to continuous data streams. The company's supply-chain-ready design and focus on actionable, AI-ready data position it to potentially transform therapy management across multiple chronic conditions.

Ultra-miniature, implantable, hermetically-sealed sensor platform for continuous wireless monitoring of physiological parameters (e.g., pressure, oxygenation, motion). Leverages semiconductor wafer-scale manufacturing for scalability and integrates sensing, ultra-low-power computing, telemetry, and wireless recharging.

InjectSense competes in the emerging space of continuous physiological monitors. In glaucoma, competitors include companies developing contact lens-based IOP sensors (e.g., Sensimed Triggerfish) and other implantable concepts. More broadly, it faces potential competition from large medtech companies with monitoring divisions (e.g., Medtronic, Abbott) and other startups targeting implantable sensors for various indications. Its key differentiator is the extreme miniaturization and semiconductor-based, scalable manufacturing approach.